Terns Pharmaceuticals Inc (TERN)
5.905
-0.24
(-3.83%)
USD |
NASDAQ |
May 17, 16:00
5.905
0.00 (0.00%)
After-Hours: 20:00
Terns Pharmaceuticals Enterprise Value: 140.94M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 140.94M |
| May 16, 2024 | 156.46M |
| May 15, 2024 | 146.76M |
| May 14, 2024 | 146.76M |
| May 13, 2024 | 140.29M |
| May 10, 2024 | 118.95M |
| May 09, 2024 | 138.35M |
| May 08, 2024 | 150.64M |
| May 07, 2024 | 131.89M |
| May 06, 2024 | 133.83M |
| May 03, 2024 | 111.19M |
| May 02, 2024 | 101.48M |
| May 01, 2024 | 87.89M |
| April 30, 2024 | 85.95M |
| April 29, 2024 | 89.19M |
| April 26, 2024 | 76.90M |
| April 25, 2024 | 59.44M |
| April 24, 2024 | 66.55M |
| April 23, 2024 | 62.67M |
| April 22, 2024 | 71.08M |
| April 19, 2024 | 54.26M |
| April 18, 2024 | 56.20M |
| April 17, 2024 | 52.86M |
| April 16, 2024 | 61.27M |
| April 15, 2024 | 86.48M |
| Date | Value |
|---|---|
| April 12, 2024 | 91.66M |
| April 11, 2024 | 96.83M |
| April 10, 2024 | 98.77M |
| April 09, 2024 | 117.52M |
| April 08, 2024 | 115.58M |
| April 05, 2024 | 107.17M |
| April 04, 2024 | 114.28M |
| April 03, 2024 | 147.26M |
| April 02, 2024 | 188.63M |
| April 01, 2024 | 218.37M |
| March 28, 2024 | 160.68M |
| March 27, 2024 | 134.81M |
| March 26, 2024 | 134.81M |
| March 25, 2024 | 151.62M |
| March 22, 2024 | 163.26M |
| March 21, 2024 | 160.03M |
| March 20, 2024 | 159.38M |
| March 19, 2024 | 125.76M |
| March 18, 2024 | 129.97M |
| March 15, 2024 | 202.05M |
| March 14, 2024 | 170.37M |
| March 13, 2024 | 194.29M |
| March 12, 2024 | 197.53M |
| March 11, 2024 | 216.92M |
| March 08, 2024 | 260.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-113.35M
Minimum
May 11 2022
808.72M
Maximum
Mar 19 2021
123.05M
Average
82.53M
Median
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 6.425B |
| Eli Lilly and Co | 755.52B |
| Pfizer Inc | 219.35B |
| Amgen Inc | 221.93B |
| Madrigal Pharmaceuticals Inc | 3.747B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.37M |
| Total Expenses (Quarterly) | 25.45M |
| EPS Diluted (Quarterly) | -0.30 |
| Earnings Yield | -21.36% |